CD274 and cancer: We observed that P+G+ samples were associated with significantly worse patient survival when compared to the P+G− across multiple cancers, indicating that a concurrent upregulation of CD274 expression and glycolysis signatures results in more aggressive disease progression in a pan-cancer manner (Figure 5).